Results of the first UK trial conducted by Professor Anthony Chu and Dr Benedetta Brazzini (Ealing Hospital and The Marylebone Clinic)

The efficacy trial was conducted between September 1016 and September 2017. Patients were assessed during three visits over an eight week period at Ealing Hospital, west London, and the Marylebone Clinic, Harley Street, using the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index DLQI).

The more widespread and severe a person’s symptoms, the higher their PASI score will be. The DLQI assesses the impact of a dermatological condition on a person’s well-being, where 30 indicates a high impact and a low level of well-being, and zero represents no impact and a high state of well-being.

There were 20 patients, 14 male, six female. Ages ranged from 11 to 79, with an average of 43.5.

 PASI

Improvement of 0-25%: 3 patients (15%)

Improvement of 26-50%: 5 patients (25%)

Improvement of 51-75%: 8 patients (40%)

Improvement of 76-100%: 4 patients (20%)

DLQI

Improvement of 0-25%: 4 patients (20%)

Improvement of 26-50%: 3 patients (15%)

Improvement of 51-75%: 4 patients (20%)

Improvement of 76-100%: 9 patients (45%)